What is the expected market size of the South Korea Ophthalmic Drugs Market in 2024?

The South Korea Ophthalmic Drugs Market is expected to be valued at 748.0 USD Million in 2024. Read More

What is the projected market value for the South Korea Ophthalmic Drugs Market by 2035?

By 2035, the South Korea Ophthalmic Drugs Market is projected to reach a value of 1496.0 USD Million. Read More

What is the expected compound annual growth rate (CAGR) for the South Korea Ophthalmic Drugs Market during the forecast period of 2025 to 2035?

The expected CAGR for the South Korea Ophthalmic Drugs Market from 2025 to 2035 is 6.504%. Read More

Which segment of the South Korea Ophthalmic Drugs Market is expected to lead in terms of market size in 2024?

In 2024, the Eye Drops segment is expected to lead the market with a value of 300.0 USD Million. Read More

What is the expected value of the Eye Ointments segment in 2035?

The Eye Ointments segment is expected to reach a market value of 300.0 USD Million by 2035. Read More

Who are the key players dominating the South Korea Ophthalmic Drugs Market?

Major players in the market include iSUN Pharma, Hanmi Pharmaceutical, and Chong Kun Dang among others. Read More

How is the market for Eye Solutions expected to grow from 2024 to 2035?

The Eye Solutions segment is anticipated to grow from 200.0 USD Million in 2024 to 400.0 USD Million in 2035. Read More

What key trends are emerging in the South Korea Ophthalmic Drugs Market?

Emerging trends include the development of innovative drug formulations and increased demand for advanced delivery systems. Read More

What challenges does the South Korea Ophthalmic Drugs Market face?

Challenges include regulatory hurdles and the need for constant innovation to meet consumer demands. Read More

What is the expected market value for Gels segment by 2035?

The Gels segment is expected to reach a value of 180.0 USD Million by 2035. Read More

South Korea Ophthalmic Drugs Market

South Korea Ophthalmic Drugs Market Research Report By Dosage Form (Eye Drops, Eye Ointments, Eye Solutions, Gels, Capsules Tablets, Others), By Product Type (Prescription Drug, OTC Drug), By Drug Class (Antibiotics, Anti-Inflammatory, Anti-Glaucoma, Others), By Indication (Glaucoma, Retinal Disorder, Dry Eye, Eye Allergy, Others) and By Distribution Channels (Hospital pharmacies, Drug stores, Online pharmacies, Others) -Forecast to 2035

Forecast Period

2025-2035

CAGR

6.5%

2023 Market Size

$ 703.54 Million

2035 Market Size

$ 1,496 Million

Pharmaceutical ● Updated July 2026 Report ID: MRFR/Pharma/43557-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

\n\tSouth\n\South Korea Ophthalmic Drugs Market, BY Dosage Form (USD Million) \n\t
1. \n\t
2. \n\t\t
3. \n
4. \n\t\tEye Drops \n\t\t
5. \n\t\t
6. \n
7. \n
8. \n\t\tEye Ointments \n\t\t
9. \n\t\t
10. \n
11. \n
12. \n\t\tEye Solutions \n\t\t
13. \n\t\t
14. \n
15. \n
16. \n\t\tGels \n\t\t
17. \n\t\t
18. \n
19. \n
20. \n\t\tCapsules \ Tablets \n\t\t
21. \n\t\t
22. \n
23. \n
24. \n\t\tOthers \n\t\t
25. \n\t
26. \n
27. \n\t
28. \n
29. \n
\n\tSouth\n\South Korea Ophthalmic Drugs Market, BY Product Type (USD Million) \n\t
1. \n\t
2. \n\t\t
3. \n
4. \n\t\tPrescription Drug \n\t\t
5. \n\t\t
6. \n
7. \n
8. \n\t\tOTC Drug \n\t\t
9. \n\t
10. \n
11. \n\t
12. \n
13. \n
\n\tSouth\n\South Korea Ophthalmic Drugs Market, BY Drug Class (USD Million) \n\t
1. \n\t
2. \n\t\t
3. \n
4. \n\t\tAntibiotics \ \n\t\t
5. \n\t\t
6. \n
7. \n
8. \n\t\tAnti-Inflammatory \n\t\t
9. \n\t\t
10. \n
11. \n
12. \n\t\tAnti-Glaucoma \ \n\t\t
13. \n\t\t
14. \n
15. \n
16. \n\t\tOthers \n\t\t
17. \n\t
18. \n
19. \n\t
20. \n
21. \n
\n\tSouth\n\South Korea Ophthalmic Drugs Market, BY Indication (USD Million) \n\t
1. \n\t
2. \n\t\t
3. \n
4. \n\t\tGlaucoma \ \n\t\t
5. \n\t\t
6. \n
7. \n
8. \n\t\tRetinal Disorder \n\t\t
9. \n\t\t
10. \n
11. \n
12. \n\t\tDry Eye \n\t\t
13. \n\t\t
14. \n
15. \n
16. \n\t\tEye Allergy \n\t\t
17. \n\t\t
18. \n
19. \n
20. \n\t\tOthers \ \n\t\t
21. \n\t
22. \n
23. \n\t
24. \n
25. \n
\n\tSouth\n\South Korea Ophthalmic Drugs Market, BY Distribution Channels (USD\n\tMillion) \n\t
1. \n\t
2. \n\t\t
3. \n
4. \n\t\tHospital pharmacies \n\t\t
5. \n\t\t
6. \n
7. \n
8. \n\t\tDrug stores \n\t\t
9. \n\t\t
10. \n
11. \n
12. \n\t\tOnline pharmacies \n\t\t
13. \n\t\t
14. \n
15. \n
16. \n\t\tOthers \n\t\t
17. \n\t
18. \n
19. \n
20. \n
21. \n
22. \n\n \n
23. \n
24. \n \n
25. \n
26. \n\t
27. \n
28. \n\tCompetitive\n\tLandscape \n\t
29. \n\t
30. \n\t\t
31. \n
32. \n\t\tOverview \ \n\t\t
33. \n\t\t
34. \n
35. \n
36. \n\t\tCompetitive Analysis \n\t\t
37. \n\t\t
38. \n
39. \n
40. \n\t\tMarket share Analysis \n\t\t
41. \n\t\t
42. \n
43. \n
44. \n\t\tMajor Growth Strategy in the\n\t\tOphthalmic Drugs Market \n\t\t
45. \n\t\t
46. \n
47. \n
48. \n\t\tCompetitive Benchmarking \n\t\t\n\t\t
49. \n\t\t
50. \n
51. \n
52. \n\t\tLeading Players in Terms of\n\t\tNumber of Developments in the Ophthalmic Drugs Market \n\t\t
53. \n\t\t
54. \n
55. \n
56. \n\t\tKey developments and growth\n\t\tstrategies \n\t\t
57. \n\t\t
58. \n\t\t\t
59. \n
60. \n\t\t\tNew Product Launch/Service\n\t\t\tDeployment \n\t\t\t
61. \n\t\t\t
62. \n
63. \n
64. \n\t\t\tMerger \ Acquisitions \n\t\t\t \n\t\t\t
65. \n\t\t\t
66. \n
67. \n
68. \n\t\t\tJoint Ventures \n\t\t\t
69. \n\t\t
70. \n
71. \n\t\t
72. \n
73. \n
74. \n\t\tMajor Players Financial\n\t\tMatrix \n\t\t
75. \n\t\t
76. \n\t\t\t
77. \n
78. \n\t\t\tSales and Operating Income \n\t\t\t \n\t\t\t
79. \n\t\t\t
80. \n
81. \n
82. \n\t\t\tMajor Players RD\n\t\t\tExpenditure. 2023 \n\t\t\t
83. \n\t\t
84. \n
85. \n\t
86. \n
87. \n\t
88. \n
89. \n
90. \n\tCompany\n\tProfiles \ \n\t
91. \n\t
92. \n\t\t
93. \n
94. \n\t\tiSUN Pharma \n\t\t
95. \n\t\t
96. \n\t\t\t
97. \n
98. \n\t\t\tFinancial Overview \n\t\t\t
99. \n\t\t\t
100. \n
101. \n
102. \n\t\t\tProducts Offered \n\t\t\t
103. \n\t\t\t
104. \n
105. \n
106. \n\t\t\tKey Developments \n\t\t\t
107. \n\t\t\t
108. \n
109. \n
110. \n\t\t\tSWOT Analysis \n\t\t\t
111. \n\t\t\t
112. \n
113. \n
114. \n\t\t\tKey Strategies \n\t\t\t
115. \n\t\t
116. \n
117. \n\t\t
118. \n
119. \n
120. \n\t\tHanmi Pharmaceutical \n\t\t
121. \n\t\t
122. \n\t\t\t
123. \n
124. \n\t\t\tFinancial Overview \ \n\t\t\t
125. \n\t\t\t
126. \n
127. \n
128. \n\t\t\tProducts Offered \n\t\t\t
129. \n\t\t\t
130. \n
131. \n
132. \n\t\t\tKey Developments \n\t\t\t
133. \n\t\t\t
134. \n
135. \n
136. \n\t\t\tSWOT Analysis \n\t\t\t
137. \n\t\t\t
138. \n
139. \n
140. \n\t\t\tKey Strategies \n\t\t\t
141. \n\t\t
142. \n
143. \n\t\t
144. \n
145. \n
146. \n\t\tChong Kun Dang \n\t\t
147. \n\t\t
148. \n\t\t\t
149. \n
150. \n\t\t\tFinancial Overview \n\t\t\t
151. \n\t\t\t
152. \n
153. \n
154. \n\t\t\tProducts Offered \n\t\t\t
155. \n\t\t\t
156. \n
157. \n
158. \n\t\t\tKey Developments \n\t\t\t
159. \n\t\t\t
160. \n
161. \n
162. \n\t\t\tSWOT Analysis \n\t\t\t
163. \n\t\t\t
164. \n
165. \n
166. \n\t\t\tKey Strategies \n\t\t\t
167. \n\t\t
168. \n
169. \n\t\t
170. \n
171. \n
172. \n\t\tAhnGook Pharmaceutical \n\t\t
173. \n\t\t
174. \n\t\t\t
175. \n
176. \n\t\t\tFinancial Overview \ \n\t\t\t
177. \n\t\t\t
178. \n
179. \n
180. \n\t\t\tProducts Offered \n\t\t\t
181. \n\t\t\t
182. \n
183. \n
184. \n\t\t\tKey Developments \n\t\t\t
185. \n\t\t\t
186. \n
187. \n
188. \n\t\t\tSWOT Analysis \n\t\t\t
189. \n\t\t\t
190. \n
191. \n
192. \n\t\t\tKey Strategies \n\t\t\t
193. \n\t\t
194. \n
195. \n\t\t
196. \n
197. \n
198. \n\t\tSungwun Pharmaceutical \n\t\t
199. \n\t\t
200. \n\t\t\t
201. \n
202. \n\t\t\tFinancial Overview \ \n\t\t\t
203. \n\t\t\t
204. \n
205. \n
206. \n\t\t\tProducts Offered \n\t\t\t
207. \n\t\t\t
208. \n
209. \n
210. \n\t\t\tKey Developments \n\t\t\t
211. \n\t\t\t
212. \n
213. \n
214. \n\t\t\tSWOT Analysis \n\t\t\t
215. \n\t\t\t
216. \n
217. \n
218. \n\t\t\tKey Strategies \n\t\t\t
219. \n\t\t
220. \n
221. \n\t\t
222. \n
223. \n
224. \n\t\tGenexine \ \n\t\t
225. \n\t\t
226. \n\t\t\t
227. \n
228. \n\t\t\tFinancial Overview \n\t\t\t
229. \n\t\t\t
230. \n
231. \n
232. \n\t\t\tProducts Offered \n\t\t\t
233. \n\t\t\t
234. \n
235. \n
236. \n\t\t\tKey Developments \n\t\t\t
237. \n\t\t\t
238. \n
239. \n
240. \n\t\t\tSWOT Analysis \n\t\t\t
241. \n\t\t\t
242. \n
243. \n
244. \n\t\t\tKey Strategies \n\t\t\t
245. \n\t\t
246. \n
247. \n\t\t
248. \n
249. \n
250. \n\t\tMyungmoon Pharmaceutical \n\t\t
251. \n\t\t
252. \n\t\t\t
253. \n
254. \n\t\t\tFinancial Overview \ \n\t\t\t
255. \n\t\t\t
256. \n
257. \n
258. \n\t\t\tProducts Offered \n\t\t\t
259. \n\t\t\t
260. \n
261. \n
262. \n\t\t\tKey Developments \n\t\t\t
263. \n\t\t\t
264. \n
265. \n
266. \n\t\t\tSWOT Analysis \n\t\t\t
267. \n\t\t\t
268. \n
269. \n
270. \n\t\t\tKey Strategies \n\t\t\t
271. \n\t\t
272. \n
273. \n\t\t
274. \n
275. \n
276. \n\t\tKyung Dong Pharmaceutical \n\t\t
277. \n\t\t
278. \n\t\t\t
279. \n
280. \n\t\t\tFinancial Overview \ \n\t\t\t
281. \n\t\t\t
282. \n
283. \n
284. \n\t\t\tProducts Offered \n\t\t\t
285. \n\t\t\t
286. \n
287. \n
288. \n\t\t\tKey Developments \n\t\t\t
289. \n\t\t\t
290. \n
291. \n
292. \n\t\t\tSWOT Analysis \n\t\t\t
293. \n\t\t\t
294. \n
295. \n
296. \n\t\t\tKey Strategies \n\t\t\t
297. \n\t\t
298. \n
299. \n\t\t
300. \n
301. \n
302. \n\t\tHugel \ \n\t\t
303. \n\t\t
304. \n\t\t\t
305. \n
306. \n\t\t\tFinancial Overview \n\t\t\t
307. \n\t\t\t
308. \n
309. \n
310. \n\t\t\tProducts Offered \n\t\t\t
311. \n\t\t\t
312. \n
313. \n
314. \n\t\t\tKey Developments \n\t\t\t
315. \n\t\t\t
316. \n
317. \n
318. \n\t\t\tSWOT Analysis \n\t\t\t
319. \n\t\t\t
320. \n
321. \n
322. \n\t\t\tKey Strategies \n\t\t\t
323. \n\t\t
324. \n
325. \n\t\t
326. \n
327. \n
328. \n\t\tDaewoong Pharmaceutical \n\t\t
329. \n\t\t
330. \n\t\t\t
331. \n
332. \n\t\t\tFinancial Overview \ \n\t\t\t
333. \n\t\t\t
334. \n
335. \n
336. \n\t\t\tProducts Offered \n\t\t\t
337. \n\t\t\t
338. \n
339. \n
340. \n\t\t\tKey Developments \n\t\t\t
341. \n\t\t\t
342. \n
343. \n
344. \n\t\t\tSWOT Analysis \n\t\t\t
345. \n\t\t\t
346. \n
347. \n
348. \n\t\t\tKey Strategies \n\t\t\t
349. \n\t\t
350. \n
351. \n\t\t
352. \n
353. \n
354. \n\t\tLG Chem \n\t\t
355. \n\t\t
356. \n\t\t\t
357. \n
358. \n\t\t\tFinancial Overview \n\t\t\t
359. \n\t\t\t
360. \n
361. \n
362. \n\t\t\tProducts Offered \n\t\t\t
363. \n\t\t\t
364. \n
365. \n
366. \n\t\t\tKey Developments \n\t\t\t
367. \n\t\t\t
368. \n
369. \n
370. \n\t\t\tSWOT Analysis \n\t\t\t
371. \n\t\t\t
372. \n
373. \n
374. \n\t\t\tKey Strategies \n\t\t\t
375. \n\t\t
376. \n
377. \n\t\t
378. \n
379. \n
380. \n\t\tMedytox \ \n\t\t
381. \n\t\t
382. \n\t\t\t
383. \n
384. \n\t\t\tFinancial Overview \n\t\t\t
385. \n\t\t\t
386. \n
387. \n
388. \n\t\t\tProducts Offered \n\t\t\t
389. \n\t\t\t
390. \n
391. \n
392. \n\t\t\tKey Developments \n\t\t\t
393. \n\t\t\t
394. \n
395. \n
396. \n\t\t\tSWOT Analysis \n\t\t\t
397. \n\t\t\t
398. \n
399. \n
400. \n\t\t\tKey Strategies \n\t\t\t
401. \n\t\t
402. \n
403. \n\t\t
404. \n
405. \n
406. \n\t\tDongA ST \n\t\t
407. \n\t\t
408. \n\t\t\t
409. \n
410. \n\t\t\tFinancial Overview \n\t\t\t
411. \n\t\t\t
412. \n
413. \n
414. \n\t\t\tProducts Offered \n\t\t\t
415. \n\t\t\t
416. \n
417. \n
418. \n\t\t\tKey Developments \n\t\t\t
419. \n\t\t\t
420. \n
421. \n
422. \n\t\t\tSWOT Analysis \n\t\t\t
423. \n\t\t\t
424. \n
425. \n
426. \n\t\t\tKey Strategies \n\t\t\t
427. \n\t\t
428. \n
429. \n\t\t
430. \n
431. \n
432. \n\t\tSamsung Bioepis \n\t\t
433. \n\t\t
434. \n\t\t\t
435. \n
436. \n\t\t\tFinancial Overview \n\t\t\t
437. \n\t\t\t
438. \n
439. \n
440. \n\t\t\tProducts Offered \n\t\t\t
441. \n\t\t\t
442. \n
443. \n
444. \n\t\t\tKey Developments \n\t\t\t
445. \n\t\t\t
446. \n
447. \n
448. \n\t\t\tSWOT Analysis \n\t\t\t
449. \n\t\t\t
450. \n
451. \n
452. \n\t\t\tKey Strategies \n\t\t\t
453. \n\t\t
454. \n
455. \n\t\t
456. \n
457. \n
458. \n\t\tKorea United Pharm \n\t\t
459. \n\t\t
460. \n\t\t\t
461. \n
462. \n\t\t\tFinancial Overview \n\t\t\t
463. \n\t\t\t
464. \n
465. \n
466. \n\t\t\tProducts Offered \n\t\t\t
467. \n\t\t\t
468. \n
469. \n
470. \n\t\t\tKey Developments \n\t\t\t
471. \n\t\t\t
472. \n
473. \n
474. \n\t\t\tSWOT Analysis \n\t\t\t
475. \n\t\t\t
476. \n
477. \n
478. \n\t\t\tKey Strategies \n\t\t\t\n\t\t\t
479. \n\t\t
480. \n
481. \n\t
482. \n
483. \n\t
484. \n
485. \n
486. \n\tAppendix\n\t \ \n\t
487. \n\t
488. \n\t\t
489. \n
490. \n\t\tReferences \n\t\t
491. \n\t\t
492. \n
493. \n
494. \n\t\tRelated Reports \n\t\t
495. \n\t
496. \n
497. \n
498. \n
499. \n
500. \nLIST\nOf tables
501. \n
502. \n\n\n
503. \n
504. \n\t
505. \n
506. \n\tLIST\n\tOF ASSUMPTIONS\n\t \n\t
507. \n\t
508. \n
509. \n
510. \n\tSouth\n\tKorea Ophthalmic Drugs Market SIZE ESTIMATES & FORECAST, BY\n\tDOSAGE FORM, 2019-2035 (USD Billions)\n\t \ \n\t
511. \n\t
512. \n
513. \n
514. \n\tSouth\n\tKorea Ophthalmic Drugs Market SIZE ESTIMATES & FORECAST, BY\n\tPRODUCT TYPE, 2019-2035 (USD Billions)\n\t \n\t
515. \n\t
516. \n
517. \n
\n\tSouth\n\tKorea Ophthalmic Drugs Market SIZE ESTIMATES & South Korea Ophthalmic Drugs Market, BY DRUG\n\tCLASS, 2019-2035 (USD Billions)\n\t \n\t
1. \n\t
2. \n
3. \n
4. \n\tSouth\n\tKorea Ophthalmic Drugs Market SIZE ESTIMATES & FORECAST, BY\n\tINDICATION, 2019-2035 (USD Billions)\n\t \ \n\t
5. \n\t
6. \n
7. \n
8. \n\tSouth\n\tKorea Ophthalmic Drugs Market SIZE ESTIMATES & FORECAST, BY\n\tDISTRIBUTION CHANNELS, 2019-2035 (USD Billions)\n\t \n\t
9. \n\t
10. \n
11. \n
12. \n\tPRODUCT\n\tLAUNCH/PRODUCT DEVELOPMENT/APPROVAL\n\t \n\t
13. \n\t
14. \n
15. \n
16. \n\tACQUISITION/PARTNERSHIP\n\t \ \n\t
17. \n
18. \n
19. \n
20. \n\n\n\n
21. \n
22. \n\n\n\n
23. \n
24. \n\n\n\n
25. \n
26. \n\n\n\n
27. \n
28. \n\n\n\n
29. \n
30. \n\n\n\n
31. \n
32. \n\n\n\n
33. \n
34. \n\n\n\n
35. \n
36. \n\n\n\n
37. \n
38. \n\n\n\n
39. \n
40. \n\n\n\n
41. \n
42. \n\n\n\n
43. \n
44. \n\n\n\n
45. \n
46. \n\n\n\n
47. \n
48. \n\n\n\n
49. \n
50. \n\n\n\n
51. \n
52. \n\n\n\n
53. \n
54. \n\n\n\n
55. \n
56. \n\n\n\n
57. \n
58. \n\n\n\n
59. \n
60. \n\n\n\n
61. \n
62. \n\n\n\n
63. \n
64. \n\n\n\n
65. \n
66. \n\n\n\n
67. \n
68. \n\n\n\n
69. \n
70. \n\n\n\n
71. \n
72. \n\n\n\n
73. \n
74. \n\n\n\n
75. \n
76. \n\n\n\n
77. \n
78. \nLIST\nOf figures
79. \n
80. \n\n\n
81. \n
82. \n\t
83. \n
84. \n\tMARKET\n\tSYNOPSIS \n\t
85. \n\t
86. \n
87. \n
88. \n\tSOUTH\n\tKOREA OPHTHALMIC DRUGS MARKET ANALYSIS BY DOSAGE FORM \n\t
89. \n\t
90. \n
91. \n
92. \n\tSOUTH\n\tKOREA OPHTHALMIC DRUGS MARKET ANALYSIS BY PRODUCT TYPE \n\t
93. \n\t
94. \n
95. \n
96. \n\tSOUTH\n\tKOREA OPHTHALMIC DRUGS MARKET ANALYSIS BY DRUG CLASS \n\t
97. \n\t
98. \n
99. \n
100. \n\tSOUTH\n\tKOREA OPHTHALMIC DRUGS MARKET ANALYSIS BY INDICATION \n\t
101. \n\t
102. \n
103. \n
104. \n\tSOUTH\n\tKOREA OPHTHALMIC DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNELS \n\t
105. \n\t
106. \n
107. \n
108. \n\tKEY\n\tBUYING CRITERIA OF OPHTHALMIC DRUGS MARKET \n\t
109. \n\t
110. \n
111. \n
112. \n\tRESEARCH\n\tPROCESS OF MRFR \n\t
113. \n\t
114. \n
115. \n
116. \n\tDRO\n\tANALYSIS OF OPHTHALMIC DRUGS MARKET \n\t
117. \n\t
118. \n
119. \n
120. \n\tDRIVERS\n\tIMPACT ANALYSIS: OPHTHALMIC DRUGS MARKET \n\t
121. \n\t
122. \n
123. \n
124. \n\tRESTRAINTS\n\tIMPACT ANALYSIS: OPHTHALMIC DRUGS MARKET \n\t
125. \n\t
126. \n
127. \n
128. \n\tSUPPLY\n\t/ VALUE CHAIN: OPHTHALMIC DRUGS MARKET \n\t
129. \n\t
130. \n
131. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DOSAGE FORM, 2024 (% SHARE) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DOSAGE FORM, 2019 TO 2035 (USD Billions) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY PRODUCT TYPE, 2024 (% SHARE) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY PRODUCT TYPE, 2019 TO 2035 (USD Billions) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DRUG CLASS, 2024 (% SHARE) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DRUG CLASS, 2019 TO 2035 (USD Billions) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY INDICATION, 2024 (% SHARE) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY INDICATION, 2019 TO 2035 (USD Billions) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DISTRIBUTION CHANNELS, 2024 (% SHARE) \n\t
1. \n\t
2. \n
3. \n
\n\tOPHTHALMIC\n\South Korea Ophthalmic Drugs Market, BY DISTRIBUTION CHANNELS, 2019 TO 2035 (USD Billions) \n\t
1. \n\t
2. \n
3. \n
4. \n\tBENCHMARKING\n\tOF MAJOR COMPETITORS \n\t
5. \n
6. \n
7. \n
8. \n\n\n\n
9. \n

Certified Researchers

Customize Report

South Korea Ophthalmic Drugs Market Segmentation

South Korea Ophthalmic Drugs Market By Dosage Form (USD Million, 2019-2035)
- Eye Drops
- Eye Ointments
- Eye Solutions
- Gels
- Capsules Tablets
- Others

South Korea Ophthalmic Drugs Market By Product Type (USD Million, 2019-2035)
- Prescription Drug
- OTC Drug

South Korea Ophthalmic Drugs Market By Drug Class (USD Million, 2019-2035)
- Antibiotics
- Anti-Inflammatory
- Anti-Glaucoma
- Others

South Korea Ophthalmic Drugs Market By Indication (USD Million, 2019-2035)
- Glaucoma
- Retinal Disorder
- Dry Eye
- Eye Allergy
- Others

South Korea Ophthalmic Drugs Market By Distribution Channels (USD Million, 2019-2035)
- Hospital pharmacies
- Drug stores
- Online pharmacies
- Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”